Apply Health-Care Tariffs Evenly, or Not at All

C ongress wrote Section 232 of the Trade Expansion Act in 1962 to protect national security, not to levy tariffs to create arbitrary winners and losers across and within critical industries. Yet that is exactly what the administration has done by delaying Section 232 duties on pharmaceuticals while moving ahead with planned tariffs on medical devices. For lawmakers who care about re-shoring, health-care security, and credible industrial policy, this approach should set off alarm bells.

Unequal tariff treatment of drugs and medical equipment makes little sense economically, strategically, or legally. It injects uncertainty into a health-care supply chain that Congress has spent years trying to stabilize. And it reinforces a hard truth that policymakers have been reluctant to admit: Tariffs are a blunt political instrument, not a realistic plan to rebuild American medical manufacturing.

Pharmaceuticals and medical devices are deeply intertwined in hospital procurement and manufacturing logistics. Treating them with separate tariff categories and different timelines ignores how health-care supply chains actually function.

A unified approach to tariff policy is not simply an ideological preference; it is a practical necessity for any serious industrial strategy. Fragmented tariff regimes create fragmented investment decisions. When the United States applies tariff authorities in inconsistent or contradictory ways, industries cannot plan, capital markets cannot price risk, and supply chains cannot adapt.

If the goal is to rebuild domestic capacity in critical health sectors, tariff policy must operate under a single guiding principle: strengthening American production while maintaining access to essential goods.

Right now, we have the opposite. Each of the government’s tariff tools is being deployed on its own timeline, with its own exemptions, and with little regard for how the combined effect will influence manufacturing decisions. Companies evaluating a domestic buildout must weigh the risk of 232 duties on particular inputs, the reach of IEEPA tariffs that vary by country, the durability of USMCA treatment of imports from Canada and Mexico, and the possibility that any of them could be changed without warning. That is not a strategic trade policy; it’s regulatory roulette.

The official rationale for delaying tariffs on pharmaceuticals is that they are too essential to risk supply chain disruptions. True enough. But if that logic holds for drugs, it applies even more forcefully to medical devices — particularly as hospitals continue to face shortages of basic equipment years after the pandemic exposed structural weaknesses in supply chains.

If the risks of supply chain disruption are real, the policy must be consistent. If the risks are exaggerated, neither tariff makes sense. Congress is entitled to ask which is the case.

Meanwhile, the Trump administration’s decision to differentiate medical tariffs doesn’t just confuse industry. It actively undermines re-shoring as well.

Congress has spent years encouraging the re-shoring of critical medical industries. The administration’s split decision effectively penalizes it. A company deciding whether to build or expand U.S. manufacturing must know whether it will face tariff exposure today, tomorrow, or five years from now.

When the administration delays tariffs for drugs but imposes them immediately on durable equipment, it sends mixed and costly signals to domestic firms throughout the health-care sector. No CEO will commit billions of dollars to a U.S. production site under those conditions. Foreign suppliers will redirect shipments toward tariff-free pharmaceuticals and away from equipment, destabilizing U.S. manufacturers of the very products Congress wants to bring home.

Incoherent trade policy also invites a dangerous precedent: Future administrations may follow in Trump’s footsteps, treating Section 232 as a discretionary industrial-policy tool rather than the narrow national-security instrument Congress intended. The more that Section 232 is stretched to serve political agendas, the harder it becomes to defend it on security grounds.

Policymakers ought to recognize that even a coherent tariff policy would struggle to rebuild pharmaceutical and medical device manufacturing. Re-shoring requires long-term regulatory clarity, targeted investment, workplace development, and consistent procurement strategies — not sporadic jolts in trade.

Tariffs disrupt supply chains. They raise costs. They can trigger foreign retaliation. What they cannot do is build factories, train workers, or restore American competitiveness in highly specialized sectors. Pausing duties on some medical imports but advancing them on others will only make re-shoring a more elusive goal.